Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma

Yamada, Daisaku; Kobayashi, Shogo; Takahashi, Hidenori; Iwagami, Yoshifumi; Akita, Hirofumi; Asukai, Kei; Shimizu, Junzo; Yamada, Terumasa; Tanemura, Masahiro; Yokoyama, Shigekazu; Tsujie, Masanori; Asaoka, Tadafumi; Takeda, Yutaka; Morimoto, Osakuni; Tomokuni, Akira; Doki, Yuichiro; Eguchi, Hidetoshi

doi:https://doi.org/10.1038/S41598-025-23185-7

Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma

Yamada, Daisaku; Kobayashi, Shogo; Takahashi, Hidenori et al.

Scientific Reports, 2025, 15, 39597

アクセス数:74件（2026-02-16 01:33 集計）

固定URL: https://hdl.handle.net/11094/103680

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
SciRep_15_39597	pdf	なし	1.66 MB	6	2026.01.30

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma
著者	NRID 1000060571396 1000060571396 ORCID 0000-0002-6702-3800 0000-0002-6702-3800 researchmap permalink dyamada79222 dyamada79222 Scopus Author ID 37008067700 37008067700 著者名 Yamada, Daisaku
	NRID 1000030452436 1000030452436 著者名 Kobayashi, Shogo
	NRID 1000090601120 1000090601120 ORCID 0000-0003-4801-3540 0000-0003-4801-3540 researchmap permalink hdnr_tkhs hdnr_tkhs Scopus Author ID 7405468781 7405468781 著者名 Takahashi, Hidenori
	NRID 1000060597441 1000060597441 著者名 Iwagami, Yoshifumi
	NRID 1000070528463 1000070528463 ORCID 0000-0002-3115-9466 0000-0002-3115-9466 researchmap permalink hirofumi_akita hirofumi_akita Scopus Author ID 12765442200 12765442200 著者名 Akita, Hirofumi
	著者名 Asukai, Kei
	著者名 Shimizu, Junzo
	著者名 Yamada, Terumasa
	NRID 1000030379250 1000030379250 著者名 Tanemura, Masahiro
	著者名 Yokoyama, Shigekazu
	著者名 Tsujie, Masanori
	NRID 1000060528470 1000060528470 著者名 Asaoka, Tadafumi
	NRID 1000090397696 1000090397696 著者名 Takeda, Yutaka
	著者名 Morimoto, Osakuni
	NRID 1000040528577 1000040528577 著者名 Tomokuni, Akira
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
	NRID 1000090542118 1000090542118 ORCID 0000-0002-2318-1129 0000-0002-2318-1129 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 著者名 Eguchi, Hidetoshi
キーワード等	GEM + nPTX
	GEM + S-1
	NAC
	Over 75 years old
	R-PDAC
	R/BR-PDAC
内容	Yamada D., Kobayashi S., Takahashi H., et al. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma. Scientific Reports 15, 39597 (2025); https://doi.org/10.1038/S41598-025-23185-7.
抄録	This study aimed to evaluate the safety and feasibility of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), for elderly patients (aged 75 years and older) with resectable and borderline resectable pancreatic ductal adenocarcinoma (R/BR-PDAC). A post hoc analysis was conducted using data from a randomized controlled trial on NAC for R/BR-PDAC (CSGO-HBP-015). Patients were divided into two groups: those aged 75 years and older (7/46 in GS and 16/48 in GA) and those under 75 years. Short-term outcomes, including resection rates, adverse events (AEs), postoperative complications, and the administration of adjuvant chemotherapy, were compared between age groups for both regimens. The incidence of AEs in patients aged 75 years and older tended to be higher than those of younger patients in both chemotherapy arms, but the differences were not statistically significant. However, the resection rates, postoperative complication rates, and the administration of adjuvant chemotherapy were not affected by age. Both regimens showed comparable safety profiles in elderly and younger cohorts. The GA and GS regimens can be safely administered as NAC for R/BR-PDAC in elderly patients without adversely affecting postoperative outcomes. These findings suggest that both regimens are feasible NAC options even for patients 75 years and older, supporting the need for further randomized controlled trials to validate these outcomes in the elderly population. Trial registration. UMIN Clinical Trials Registry UMIN000021484. This trial began in April 2016, and first registration (First Posted date) is 01/04/2016.
出版者	Nature Research
収録物名	Scientific Reports
巻(号)	15
ページ	39597
刊行年月	2025-11-12
言語	英語
ハンドルURL	https://hdl.handle.net/11094/103680
eISSN	20452322
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1038/S41598-025-23185-7
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Scientific Reports. 2025, 15, p. 39597
DC.title	Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma
DC.creator	Yamada, Daisaku
	Kobayashi, Shogo
	Takahashi, Hidenori
	Iwagami, Yoshifumi
	Akita, Hirofumi
	Asukai, Kei
	Shimizu, Junzo
	Yamada, Terumasa
	Tanemura, Masahiro
	Yokoyama, Shigekazu
	Tsujie, Masanori
	Asaoka, Tadafumi
	Takeda, Yutaka
	Morimoto, Osakuni
	Tomokuni, Akira
	Doki, Yuichiro
	Eguchi, Hidetoshi
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-11-12
DC.identifier	https://doi.org/10.1038/S41598-025-23185-7
DC.subject	GEM + nPTX
	GEM + S-1
	NAC
	Over 75 years old
	R-PDAC
	R/BR-PDAC
DC.description	Yamada D., Kobayashi S., Takahashi H., et al. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma. Scientific Reports 15, 39597 (2025); https://doi.org/10.1038/S41598-025-23185-7.
DCTERMS.abstract	This study aimed to evaluate the safety and feasibility of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), for elderly patients (aged 75 years and older) with resectable and borderline resectable pancreatic ductal adenocarcinoma (R/BR-PDAC). A post hoc analysis was conducted using data from a randomized controlled trial on NAC for R/BR-PDAC (CSGO-HBP-015). Patients were divided into two groups: those aged 75 years and older (7/46 in GS and 16/48 in GA) and those under 75 years. Short-term outcomes, including resection rates, adverse events (AEs), postoperative complications, and the administration of adjuvant chemotherapy, were compared between age groups for both regimens. The incidence of AEs in patients aged 75 years and older tended to be higher than those of younger patients in both chemotherapy arms, but the differences were not statistically significant. However, the resection rates, postoperative complication rates, and the administration of adjuvant chemotherapy were not affected by age. Both regimens showed comparable safety profiles in elderly and younger cohorts. The GA and GS regimens can be safely administered as NAC for R/BR-PDAC in elderly patients without adversely affecting postoperative outcomes. These findings suggest that both regimens are feasible NAC options even for patients 75 years and older, supporting the need for further randomized controlled trials to validate these outcomes in the elderly population. Trial registration. UMIN Clinical Trials Registry UMIN000021484. This trial began in April 2016, and first registration (First Posted date) is 01/04/2016.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	103680
citation_title	Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma
citation_author	Yamada, Daisaku
	Kobayashi, Shogo
	Takahashi, Hidenori
	Iwagami, Yoshifumi
	Akita, Hirofumi
	Asukai, Kei
	Shimizu, Junzo
	Yamada, Terumasa
	Tanemura, Masahiro
	Yokoyama, Shigekazu
	Tsujie, Masanori
	Asaoka, Tadafumi
	Takeda, Yutaka
	Morimoto, Osakuni
	Tomokuni, Akira
	Doki, Yuichiro
	Eguchi, Hidetoshi
citation_publisher	Nature Research
citation_language	英語
citation_date	2025-11-12
citation_journal_title	Scientific Reports
citation_volume	15
citation_firstpage	39597
citation_doi	https://doi.org/10.1038/S41598-025-23185-7
citation_public_url	https://hdl.handle.net/11094/103680

Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma

閲覧可能ファイル

論文情報

論文詳細を表示